

Applicants: Ron S. Israeli et al.
Serial No.: 08/403,803
Filed : March 17, 1995
Page 2

applicants' right to pursue the subject matter of these claims in a later-filed application. Please also amend claims 113-115 and 119-122 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material as follows:

61
--113. (Amended) An isolated nucleic acid which encodes an antigenic prostate specific membrane antigen polypeptide comprising consecutive amino acids, the sequence of which amino acids corresponds to the sequence of all or less than all of an outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is set forth within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus, provided that the polypeptide is characterized by antigenicity.--

--114. (Amended) An isolated nucleic acid which encodes an antigenic prostate specific membrane antigen polypeptide consisting essentially of consecutive amino acids, the sequence of which corresponds to the sequence of [the] all or less than all of an outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is set forth within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus of the polypeptide, which polypeptide is characterized by antigenicity and comprises each of the following sequences:

- (a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35);
- (b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36); and
- (c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).--

--115. (Amended) An isolated nucleic acid which encodes an antigenic prostate specific membrane antigen polypeptide

G¹
consisting essentially of a fragment of prostate specific membrane antigen, which fragment has a sequence which is the same as the sequence of [the] all or less than all of an antigenic outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is included within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus of the fragment, which fragment is characterized by antigenicity and comprises each of the following sequences:

- (a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35);
- (b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36); and
- (c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).--

G²
--119. (Amended) The isolated nucleic acid of claim 116, [wherein the isolated nucleic acid encodes a fragment of prostate specific membrane antigen, which] wherein the fragment has a sequence which is the same as [the] a sequence of all or less than all of an [the antigenic] outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is set forth within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus.--

--120. (Amended) An isolated nucleic acid which encodes an antigenic fragment of prostate specific membrane antigen, which fragment is characterized by antigenicity and has a sequence which is the same as [the] a sequence of all or less than all of an [the] outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is set forth within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus.--

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 08/403,803
Filing Date: March 17, 1995
Page 4

- 62
- 121. An isolated nucleic acid which is at least 15 nucleotides in length and specifically hybridizes to the nucleic acid of any one of claims [106-115] 113-120.--
- 122. A vector which comprises the isolated nucleic acid of any one of claims [106-115] 113-120.--

REMARKS

Initially applicants would like to thank the Examiner for the courtesy extended during the interview held on November 21, 2000 and attended by John P. White, Spencer Schneider, S. Leslie Misrock, Paul Maddon, Edward Gates and William Goeckler. Applicants believe this interview was most helpful in advancing prosecution of this application and that based on the amendments set forth above, applicants understand that the claims are likely in condition for allowance.

Claims 100-126 are pending in the subject application. Applicants have hereinabove canceled claims 106-112 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in a later-filed application. Applicants have also amended claims 113-115 and 119-122. Support for these amendments may be found inter alia in the specification as follows: claims 113-115 and 119-120: page 22, lines 9-20; page 44, line 14; page 6, lines 15; page 53, line 20 to page 54, line 7; page 31, lines 14-15; and page 32, lines 24-27. This amendment does not involve any issue of new matter. Therefore, entry of this amendment is respectfully requested such that claims 100-105 and 113-126 will be pending.